Showing 2331-2340 of 5644 results for "".
- Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meetinghttps://modernod.com/news/tarsus-presents-new-findings-from-two-studies-that-demonstrate-the-impact-of-demodex-blepharitis-at-the-arvo-2022-annual-meeting/2480847/Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with
- Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technologyhttps://modernod.com/news/clearside-biomedical-poster-presentation-at-arvo-2022-annual-meeting-demonstrates-versatility-of-suprachoroidal-delivery-technology/2480845/Clearside Biomedical, Inc. announced that several poster presentations were delivered on Clearside’s proprietary suprachoroidal delivery platform, XIPERE®, and gene therapy delivery utilizing Clearside’s SCS Microinjector® at the Association for Research in Vision and Ophthalm
- Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03https://modernod.com/news/bausch-lomb-presents-data-from-second-pivotal-phase-3-trial-of-investigational-treatment-nov03-at-arvo/2480837/Bausch + Lomb and Novaliq announced that data from the second pivotal phase 3 trial (MOJAVE) of investigational treatment NOV03 (perfluorohexyloctane) were presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. NOV03 is being investigated as a first-in-c
- Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-detailed-18-month-results-from-phase-3-derby-and-oaks-studies-of-pegcetacoplan-for-geographic-atrophy-ga-at-arvo/2480830/Apellis Pharmaceuticals announced detailed, longer-term data from the phase 3 DERBY and OAKS studies of intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Monthly and
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these
- SightGlass Vision Presents 24-Month Data Demonstrating Myopia Control Efficacy for Vision Spectacle Lenseshttps://modernod.com/news/sightglass-vision-presents-24-month-data-demonstrating-myopia-control-efficacy-for-vision-spectacle-lenses/2480823/Spectacles that use SightGlass Vision Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children,[1] based on 24-month interim data from its pivotal c
- Nicox Presents Phase 2 Results on NCX 4251 and New Nonclinical Evidence of Improved Hemodynamic and Retinal Cell Physiology on NCX 470https://modernod.com/news/nicox-presents-phase-2-results-on-ncx-4251-and-new-nonclinical-evidence-of-improved-hemodynamic-and-retinal-cell-physiology-on-ncx-470/2480822/Nicox SA announced poster presentations highlighting the effect of NCX 4251 in patients with dry eye disease as well as new nonclinical evidence of neuroprotective activity on NCX 470 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 annual meeting, one of the key scien
- Registration Now Open for Neuro-Optometric Rehabilitation Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-annual-conference/2480810/Registration is now open for the Neuro-Optometric Rehabilitatio
- Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022https://modernod.com/news/tarsus-presents-results-of-two-studies-highlighting-demodex-blepharitis-patient-impact-and-burden-at-the-ascrs-2022-annual-meeting/2480803/Tarsus Pharmaceuticals presented data from its Atlas Continuation study on the negative impacts to daily life and visual function, and preliminary findings from its Pandora study on pathogenic bacterial count, for patients with Demodex blepharitis at the American S
- CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgerieshttps://modernod.com/news/corneagen-advances-next-generation-of-dsek-surgery-innovation/2480789/CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries. “We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in